Solventum Corp reported revenue of $2.21B for the period ended 2026-06-30, +2.2% year on year. Net income was $0.09B, a 4.2% net margin on a 58.2% gross margin. The largest revenue line is Infection Prevention And Surgical Solutions at 38% of the total. Free cash flow for the period was $0.14B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $2.21B | +2.2% |
| Gross profit | $1.29B | — |
| Operating income | $0.18B | — |
| Net income | $0.09B | +2.2% |
| Gross margin | 58.2% | Net margin 4.2% |
| Revenue Q/Q | +10.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| Infection Prevention And Surgical Solutions | $0.84B | 37.8% |
| Advanced Wound Care | $0.54B | 24.3% |
| Dental Solutions | $0.40B | 17.9% |
| Health Information Systems | $0.35B | 16.0% |
| Purification And Filtration | $0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.92B | 41.8% |
| R&D | $0.18B | 8.1% |
| SG&A | $0.93B | 42.0% |
| Tax & other | $0.09B | 4.0% |
| Item | Amount |
|---|---|
| Total assets | $14.24B |
| Total liabilities | $9.44B |
| Shareholders' equity | $4.80B |
| Equity / assets | 33.7% |
| Operating cash flow | $0.23B |
| Capital expenditure | $0.08B |
| Free cash flow | $0.14B |
| Cash conversion (OCF / net income) | 247% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
SO ・ LUV ・ SWK ・ SBUX ・ STT ・ STLD ・ STE ・ SYK ・ SMCI ・ SYF ・ SNPS ・ SYY
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies